Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW)：483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(18)

カスタマーフィードバック(9)

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)		 CDK4/CyclinD1 [1]
(Cell-free assay)		 CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NF3FWGlMcW6jc3WgRZN{[Xl? MnHhNlQhcA>? NWS0ZXlMUW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2= MmXoNlQ3PDFzMEO=
COLO205 NYi2PJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\NOFczKGh? NH;UVo9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>? MkX5NlQ3PDFzMEO=
U937 NYDBRVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPoPGNiPzJiaB?= M{LRV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5zNDFOwG0> Mn\6NlQ3PDFzMEO=
MOLM13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHKO|IhcA>? NVLRTmc6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? NHfJNWozPDZ2MUGwNy=>
MOLM13 M4LyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;PO|IhcA>? NFrSeFZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP M4Cxc|I1PjRzMUCz
MDA-MB-435 NH\LTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjM[G4zPCCq Ml;aTWM2OD1yLkG2JO69VQ>? MnrsNVU5ODF6M{G=
K562 NIrFWmREgXSxdH;4bYMhSXO|YYm= MnfMPVYhcA>? MoDhSG1UVw>? NFjON5dKSzVyPUKg{txO NY\IWlg3OjR2MUe1OlY>
DU145 M1vXfWN6fG:2b4jpZ{BCe3OjeR?= M2PMbFk3KGh? MYjEUXNQ MYnJR|UxRTdwNTFOwG0> MoC2NlQ1OTd3Nk[=
MDA-MB-231 NHvyPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz4XZEyKM7:TR?= NXrDTJVIOjRiaB?= MX;EUXNQ MmnkR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NUDwRXFvOjR2MUe1OlY>
MCF7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;UUYMyKM7:TR?= NFXm[FgzPCCq NU\zZWE5TE2VTx?= MlnNR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NX\ZU|c1OjR2MUe1OlY>
MCF7 NEnhZplMcW6jc3WgRZN{[Xl? NWD5UlBIPSEQvF2= Mn\zNlQhcA>? MULEUXNQ MnnxTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= NFSwbJQzPDRzN{W2Oi=>
MDA-MB-231 Mn2wT4lv[XOnIFHzd4F6 NF7yOGM2KM7:TR?= Mn;rNlQhcA>? MYTEUXNQ M{nqO2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= Mnz6NlQ1OTd3Nk[=
MDA-MB-231 NWPZeZZRTnWwY4Tpc44hSXO|YYm= NWP6SpVKOS1zMDFOwG0> NY[xe44{OjRiaB?= NX\IeIliTE2VTx?= M17KToRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= Ml7BNlQ1OTd3Nk[=
MCF7 MVTGeY5kfGmxbjDBd5NigQ>? NWHFOHhIOS1zMDFOwG0> M{DvbFI1KGh? Mn7zSG1UVw>? M2LuboRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NVT1SId2OjR2MUe1OlY>
MDA-MB-231 MYDGeY5kfGmxbjDBd5NigQ>? MoLTNE42NTFizszN Mn61OFghcA>? MlfVSG1UVw>? M1PkOYhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm MXKyOFQyPzV4Nh?=
MCF7 NYftVZgxTnWwY4Tpc44hSXO|YYm= M4j4c|AvPS1zIN88US=> Ml;DOFghcA>? M3vZbWROW09? NUn3T3F[cGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? MUeyOFQyPzV4Nh?=
697 NGTzbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF2OD6zPEBvVQ>? MoDJV2FPT0WU
P12-ICHIKAWA NV;mbI1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPqNVNmUUN3ME25Ok4xPCCwTR?= M3vocHNCVkeHUh?=
NB69 Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rHc2lEPTB;MU[xMlghdk1? M17J[HNCVkeHUh?=
EoL-1 NXO5eW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF6Nz6yOkBvVQ>? MmX3V2FPT0WU
BHT-101 NXT0Z5FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G0NGlEPTB;MUm4MlI2KG6P M1XyU3NCVkeHUh?=
SK-NEP-1 NXvve|M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv2TWM2OD1{MkCuNFIhdk1? MWLTRW5ITVJ?
MHH-NB-11 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjVNFd4UUN3ME2yNlAvOTlibl2= MoPKV2FPT0WU
AsPC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHJOJJKSzVyPUK1Nk42OyCwTR?= MVXTRW5ITVJ?
ES1 M1e5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;ocHpKSzVyPUK1Ok4zPSCwTR?= MV3TRW5ITVJ?
LAMA-84 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHznVJFKSzVyPUK1PE4yQSCwTR?= MXvTRW5ITVJ?
MOLT-16 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljGTWM2OD1{NUiuOFkhdk1? NYfyS|ZuW0GQR1XS
ES7 NX3G[|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7kTWM2OD1{N{OuNFkhdk1? M37uVXNCVkeHUh?=
KY821 NULkWolyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNzND6xJI5O NH\Eb5JUSU6JRWK=
RT-112 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDyXVk2UUN3ME2zNlEvODVibl2= M{HCOHNCVkeHUh?=
HL-60 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmyTWM2OD1|NECuOlYhdk1? MlnGV2FPT0WU
MOLT-4 MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN2NT6xN{BvVQ>? NHnUTY5USU6JRWK=
KARPAS-45 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT5W5ZKSzVyPUO3Ok4yPiCwTR?= MVjTRW5ITVJ?
SK-N-AS MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[we2dYUUN3ME2zPFcvQDNibl2= NWPib5lRW0GQR1XS
CTB-1 NVTY[IVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDidXhLUUN3ME20NFUvODJibl2= NWDqTJpDW0GQR1XS
NKM-1 M33ldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKwTWM2OD12MUGuPFkhdk1? NXLiT21bW0GQR1XS
HTC-C3 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrwSVNKSzVyPUSzNk46PSCwTR?= MoDBV2FPT0WU
BE-13 NFjyZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfLTWM2OD12NESuNlchdk1? MXTTRW5ITVJ?
KOSC-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzmVHVEUUN3ME20OlYvQSCwTR?= MlTSV2FPT0WU
NB14 NGryUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6OYNKSzVyPUS4N{42QCCwTR?= NV76SVBnW0GQR1XS
CAL-27 NGrmdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\VTWM2OD12OUSuOVkhdk1? M3G3Z3NCVkeHUh?=
H9 M{mzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfK[FFKSzVyPUS5OU41OyCwTR?= MnW1V2FPT0WU
RS4-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M12zRmlEPTB;NUC0Mlc{KG6P M4XFbnNCVkeHUh?=
PA-1 M2PQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTVyOT64OkBvVQ>? NHfaV49USU6JRWK=
MV-4-11 M3HOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuwb|A4UUN3ME21NVMvQDVibl2= MVXTRW5ITVJ?
OS-RC-2 Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDHcnJ3UUN3ME21NlEvPjJibl2= NHfvbpVUSU6JRWK=
RPMI-8226 M2LyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\xNGlEPTB;NUK2Mlg3KG6P M3\BfXNCVkeHUh?=
HGC-27 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnBS3pGUUN3ME21OlQvQTlibl2= MVnTRW5ITVJ?
CHP-212 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTV7Mz61PUBvVQ>? NWDpcGNvW0GQR1XS
NB10 NHrqfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\hZYJ1UUN3ME21PVkvOThibl2= NWPz[pNpW0GQR1XS
HH M2TLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7TUZRpUUN3ME21PVkvPDNibl2= NHXZS41USU6JRWK=
EW-16 NYDnXZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPxWlNGUUN3ME22NFMvPTJibl2= NXnQdpBoW0GQR1XS
ES8 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDPTWM2OD14MEWuNlEhdk1? MniwV2FPT0WU
HAL-01 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZyNT62O{BvVQ>? MWrTRW5ITVJ?
A204 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HwcWlEPTB;NkOzMlkyKG6P M3LBZXNCVkeHUh?=
MHH-PREB-1 NGDWOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe1[HRRUUN3ME22N|YvQTlibl2= NYTkfXR{W0GQR1XS
EM-2 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZ3MD62OEBvVQ>? NUCwT5FEW0GQR1XS
BV-173 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT5elRyUUN3ME22OVIvPDhibl2= M{\oO3NCVkeHUh?=
ONS-76 NXzz[pdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPVTnVKSzVyPU[3O{45OiCwTR?= MXnTRW5ITVJ?
KM-H2 M2GwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnywTWM2OD14OUWuOVQhdk1? NVrHdWo6W0GQR1XS
D-263MG NUPwdI4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTdzNz6xNkBvVQ>? MVTTRW5ITVJ?
ES3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTd{OD65N{BvVQ>? NYjKblVlW0GQR1XS
VA-ES-BJ NGC3coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC5Onh4UUN3ME23N|IvOjdibl2= MVHTRW5ITVJ?
NBsusSR MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTd2Mj65PUBvVQ>? NWLacWRyW0GQR1XS
NCI-H520 NFPmdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHMTWM2OD15NE[uOVIhdk1? NFjRc3BUSU6JRWK=
ES5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[1TWM2OD15NUKuPEBvVQ>? Mkf4V2FPT0WU
T-24 M1Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV22eGk4UUN3ME23O|gvPzFibl2= M1Tpd3NCVkeHUh?=
SW962 NYXuWmF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRThyOD62N{BvVQ>? MnzpV2FPT0WU
EW-3 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Zb4JKSzVyPUiwPE44PiCwTR?= M{[2UHNCVkeHUh?=
RXF393 M2LtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\oRpBkUUN3ME24NVIvPzlibl2= MnjaV2FPT0WU
U251 NXz1bWVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\ydWlEPTB;OEGzMlg5KG6P M1;sR3NCVkeHUh?=
CAMA-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrwT|BKSzVyPUizN{46PCCwTR?= NIfsTYRUSU6JRWK=
JVM-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHnTWM2OD16NUGuO|ghdk1? NVPKZ5RSW0GQR1XS
COLO-800 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTh7Nz63PEBvVQ>? M3;venNCVkeHUh?=
OVCAR-5 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTlyMD6xJI5O NGrrPINUSU6JRWK=
LB1047-RCC M4qyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTl{Nz61OkBvVQ>? NHzhSldUSU6JRWK=
SW954 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\uTWM2OD17MkmuOFEhdk1? M1TQeHNCVkeHUh?=
J-RT3-T3-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHGToZKSzVyPUmzOk4xPiCwTR?= NXTUVIxTW0GQR1XS
Mewo MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml25TWM2OD17M{[uOkBvVQ>? MmXCV2FPT0WU
NCI-H1770 NEnJdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PrdWlEPTB;OUSwMlU2KG6P Mn63V2FPT0WU
HO-1-N-1 M3fCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXkcZBPUUN3ME25OlIvQDFibl2= MnrIV2FPT0WU
HSC-3 M1TYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml60TWM2OD17Nk[uOFghdk1? MWXTRW5ITVJ?
TYK-nu MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDFTWM2OD17OUiuNlUhdk1? MY\TRW5ITVJ?
KYSE-150 NWHyT4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3vTJlwUUN3ME2xMlAxODd4IN88US=> NUP4b4RqW0GQR1XS
SN12C NGfKXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfxdY5KSzVyPUGuNFA5PzVizszN MlHrV2FPT0WU
MOLT-13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwMEG0NlEh|ryP MknEV2FPT0WU
TE-11 NYLMc3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwMES4NVIh|ryP M2jjU3NCVkeHUh?=
DB NUX4WI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwMEeyO|Mh|ryP MlTRV2FPT0WU
CAL-39 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6xUnVKSzVyPUGuNFc2OjJizszN NGfUOolUSU6JRWK=
A3-KAW MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwMEi0NFgh|ryP NIPUZ3hUSU6JRWK=
CHP-134 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyyOGNKSzVyPUGuNVE5ODdizszN MmrHV2FPT0WU
TGW MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTmTWM2OD1zLkGyN|k2KM7:TR?= NHnjPJlUSU6JRWK=
QIMR-WIL M37LUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwMUOxN|Qh|ryP MmHxV2FPT0WU
NCI-SNU-1 NF7WXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3sTWM2OD1zLkG2N|U1KM7:TR?= Mn3NV2FPT0WU
CGTH-W-1 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfQSIVKSzVyPUGuNVcyQDZizszN NI\5c2lUSU6JRWK=
MHH-ES-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPITWM2OD1zLkG3PVg3KM7:TR?= NH\leFBUSU6JRWK=
LB2241-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zEZ2lEPTB;MT6xPFYzKM7:TR?= M37WbXNCVkeHUh?=
ML-2 NXeycXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwMkC3N|Qh|ryP MWXTRW5ITVJ?
COR-L23 NGf4WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO1W4pKSzVyPUGuNlI6OzNizszN M{LXfXNCVkeHUh?=
BFTC-905 M3qwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTWVpduUUN3ME2xMlI1OjZ5IN88US=> NGXIOIFUSU6JRWK=
Hs-578-T NF[0W2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLmSlFJUUN3ME2xMlI2QDF5IN88US=> M1vMcnNCVkeHUh?=
KG-1 NFvJV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjWV4hKSzVyPUGuNlY3QDZizszN MVXTRW5ITVJ?
HEL M2riR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KwU2lEPTB;MT6yPVM{QCEQvF2= MmP2V2FPT0WU
A549 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv0ZYNKSzVyPUGuNlk{QTlizszN NGjCVJJUSU6JRWK=
COLO-741 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXUdJFUUUN3ME2xMlMzODh7IN88US=> NVT5eJBwW0GQR1XS
PC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW5e|JKSzVyPUGuN|UzOjFizszN NELVWIhUSU6JRWK=
HOS NIT4S4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoToTWM2OD1zLkO1Nlk3KM7:TR?= MYXTRW5ITVJ?
HT-1080 NFrJZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqzTWM2OD1zLkO3OVE6KM7:TR?= M4nsSHNCVkeHUh?=
TE-8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGroW3pKSzVyPUGuOFE4PzRizszN NUm3elJ2W0GQR1XS
BHY MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNE[5NlMh|ryP NWLyVnhKW0GQR1XS
BB65-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwNUC1Nlgh|ryP MUDTRW5ITVJ?
HN NWLnNJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwNUSwO|Eh|ryP NE[wN45USU6JRWK=
NCI-H441 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXCTWM2OD1zLkW0PVA4KM7:TR?= M1\3fnNCVkeHUh?=
RPMI-8866 M4W2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnZOYZKSzVyPUGuOVg2ODdizszN NX7MdWNpW0GQR1XS
CAL-62 M1PkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDPdI8xUUN3ME2xMlYxQDZ{IN88US=> MkfoV2FPT0WU
MG-63 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHIVHpKSzVyPUGuOlE5OTNizszN MX\TRW5ITVJ?
SK-LU-1 NIS2boZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXvTZFKSzVyPUGuOlIyPTJizszN M1HJUnNCVkeHUh?=
BCPAP M3G5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkV|lKSzVyPUGuOlY1PTdizszN M17hd3NCVkeHUh?=
22RV1 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLZRmVKSzVyPUGuOlc5PDNizszN Mn7pV2FPT0WU
T47D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\NW2lEPTB;MT62PFA3OSEQvF2= NF7kV4JUSU6JRWK=
MSTO-211H M4L1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCyWZpKSzVyPUGuOlk3ODNizszN MXrTRW5ITVJ?
DEL NVXsR4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwN{CyO|Mh|ryP NXTQN|d7W0GQR1XS
H4 NH;QcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrNZVKSzVyPUGuO|MzOTJizszN M4LvPXNCVkeHUh?=
CAL-51 M2ToUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle1TWM2OD1zLke0PFU2KM7:TR?= NY\NdFJoW0GQR1XS
ABC-1 NGrkb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPRTWM2OD1zLke4OVgzKM7:TR?= MmPqV2FPT0WU
MZ2-MEL NXn2cXE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLCTWM2OD1zLke5OVQzKM7:TR?= NH71cZZUSU6JRWK=
YKG-1 M{\KXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwOEGwOlEh|ryP MUjTRW5ITVJ?
KM12 M1\WU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TqbWlEPTB;MT64NVYxOiEQvF2= M2TSdnNCVkeHUh?=
L-363 NWPheZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwOEe0NVIh|ryP M{f6WXNCVkeHUh?=
KU812 M3;yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;FOGlEPTB;MT64PVI5OiEQvF2= M3\5cnNCVkeHUh?=
LOXIMVI M2nxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknLTWM2OD1zLkmxNlI5KM7:TR?= MUnTRW5ITVJ?
G-401 NE[1WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPKUXdKUUN3ME2xMlkzPDJ6IN88US=> MUHTRW5ITVJ?
SW780 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\KbnJKSzVyPUGuPVYzPDZizszN M4rUPHNCVkeHUh?=
SW872 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G4W2lEPTB;MT65PFM{KM7:TR?= M3jGRXNCVkeHUh?=
NB7 M4e4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGwRnZKSzVyPUGuPVk{OjNizszN NIfpZ3lUSU6JRWK=
T98G NUTQ[lJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJwMEC2OlYh|ryP M2XFbnNCVkeHUh?=
SW1710 NWXlUlllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vyN2lEPTB;Mj6wOlk1PSEQvF2= NXjYTGZFW0GQR1XS
NCI-H1573 NF\OOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTL[YpIUUN3ME2yMlA4Ojl6IN88US=> M2Ppe3NCVkeHUh?=
KE-37 NWmwO|g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rIU2lEPTB;Mj6wPFk2OSEQvF2= NEH2NlVUSU6JRWK=
786-0 M3zUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJwMUW0N|kh|ryP MVnTRW5ITVJ?
SAS M1vPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwMkCzO|Qh|ryP NGjPfFVUSU6JRWK=
CAL-54 M1[zRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwMkC0NVMh|ryP MUfTRW5ITVJ?
SF268 NFTufI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjkU49YUUN3ME2yMlI{OTJ{IN88US=> MWnTRW5ITVJ?
SW620 NXqzTmFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwMk[xOlkh|ryP MmnLV2FPT0WU
MN-60 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwM{GwOkDPxE1? MYPTRW5ITVJ?
EFO-27 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\3e4twUUN3ME2yMlMzODV6IN88US=> MXnTRW5ITVJ?
NCI-H747 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDkfZREUUN3ME2yMlMzOTl7IN88US=> MoHvV2FPT0WU
HCC2218 NFLNR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fNRWlEPTB;Mj6zOVM4PCEQvF2= MYPTRW5ITVJ?
MIA-PaCa-2 M3XsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrHWmpKSzVyPUKuN|Y1OzdizszN NYTWflJTW0GQR1XS
SJSA-1 NIP0SmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJwM{e3PVYh|ryP MoHFV2FPT0WU
RKO NE[1TIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnLTWM2OD1{LkO4OFk3KM7:TR?= NWjMUG5IW0GQR1XS
NB6 NWfTboZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXkTWM2OD1{LkSwN|c1KM7:TR?= NYDEVXh5W0GQR1XS
ES4 NETpbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGzb2pjUUN3ME2yMlQ2PDJ{IN88US=> M{D2RnNCVkeHUh?=
EGI-1 M3\HUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDGUlRmUUN3ME2yMlQ3QDh|IN88US=> NHT0cohUSU6JRWK=
CTV-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\FTWM2OD1{LkWyO|c{KM7:TR?= NXjHWm5lW0GQR1XS
NCI-H1355 NFjKWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjBR21zUUN3ME2yMlU2QTVzIN88US=> MV7TRW5ITVJ?
GT3TKB NX3idppsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwNUmxPVkh|ryP NED4R4NUSU6JRWK=
SK-HEP-1 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7TTWM2OD1{LkW5NlY3KM7:TR?= MXfTRW5ITVJ?
GAMG NV\j[I9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4SYVKUUN3ME2yMlU6Ozl2IN88US=> NXzQZnBCW0GQR1XS
SK-MES-1 NIiwXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfXT3ZzUUN3ME2yMlYyQDB|IN88US=> M4DLSnNCVkeHUh?=
RO82-W-1 M3n1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DmfWlEPTB;Mj62NlA2PyEQvF2= MkCyV2FPT0WU
ECC10 NGfjb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH3TWM2OD1{LkewNlA3KM7:TR?= NWriS3Q{W0GQR1XS
MCF7 M4m3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2ZXFKSzVyPUKuO|E1PjRizszN NYfoOFFFW0GQR1XS
D-283MED M1rXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XJO2lEPTB;Mj63NlQ{KM7:TR?= M4WxXXNCVkeHUh?=
RPMI-7951 NFf1XlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO5TWM2OD1{Lke1Olk1KM7:TR?= NFOyOZpUSU6JRWK=
Ramos-2G6-4C10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDQTWM2OD1{Lke3NFk6KM7:TR?= NX6xe4NCW0GQR1XS
KGN MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr5TXh[UUN3ME2yMlgyQDh2IN88US=> MmTWV2FPT0WU
NUGC-3 M3rHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LB[2lEPTB;Mj64NlUxPSEQvF2= NXvpbYprW0GQR1XS
NCI-H292 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTwTWM2OD1{Lki1NFU{KM7:TR?= MoPaV2FPT0WU
Becker NVTKdJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf5TFFTUUN3ME2yMlk2QDN{IN88US=> NUGxe3VIW0GQR1XS
NCI-H1299 NVWx[G1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPtPHNKSzVyPUOuNFUzPjNizszN MXXTRW5ITVJ?
ETK-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzOc|JFUUN3ME2zMlA2PDNizszN NUDVZXdbW0GQR1XS
TK10 NGLHT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jhUGlEPTB;Mz6yNFE3PSEQvF2= MVPTRW5ITVJ?
VMRC-RCZ MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNwM{[0PFgh|ryP MXjTRW5ITVJ?
YH-13 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTNwNESwO|kh|ryP MXzTRW5ITVJ?
DU-145 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[4[nl{UUN3ME2zMlQ3OjZ7IN88US=> MoTMV2FPT0WU
SW1088 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7GS|B1UUN3ME2zMlQ4PDdizszN NYLTeJl7W0GQR1XS
HOP-92 M1vOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\0TWM2OD1|LkWwN|QzKM7:TR?= M2rJSnNCVkeHUh?=
KP-N-YS M4XG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[5d45KSzVyPUOuOlIyOzlizszN MY\TRW5ITVJ?
NCI-H460 M370dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXjToc{UUN3ME2zMlY3PzNizszN NV\mNmpRW0GQR1XS
U-2-OS NHjHOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\WTWM2OD1|LkeyOVM2KM7:TR?= NUHmbphQW0GQR1XS
A101D NIm0S5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDufGpKSzVyPUOuO|Y6OzZizszN MnziV2FPT0WU
MDA-MB-231 NU\XZ41JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnNTWM2OD1|LkixPVUyKM7:TR?= M4\wN3NCVkeHUh?=
IST-MES1 NIPRWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3lSJFKSzVyPUOuPFMzKM7:TR?= NV32VJVHW0GQR1XS
COR-L105 M{DLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzjTWM2OD12LkCxPEDPxE1? MV;TRW5ITVJ?
NCI-H1437 NX\YSnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXGOYhKSzVyPUSuNFI{ODJizszN NF7oUHhUSU6JRWK=
CAL-85-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjsXWFKSzVyPUSuNFI1PjFizszN M3nFSHNCVkeHUh?=
MZ1-PC NFfyNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX0TWM2OD12LkG4OVU3KM7:TR?= Mk\sV2FPT0WU
VM-CUB-1 NFzBT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrUcpdKSzVyPUSuN|EzQDRizszN MX3TRW5ITVJ?
CHL-1 NVPQOpFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3QTWM2OD12LkOyNVY6KM7:TR?= MkXKV2FPT0WU
MDA-MB-361 M4HHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLqXmFtUUN3ME20MlM{OTV|IN88US=> NEL1XWZUSU6JRWK=
NCI-H661 NXXKSXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn4TWM2OD12LkWwNFkzKM7:TR?= NUf4eHhCW0GQR1XS
EW-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqyeoZKSzVyPUSuOVIzOzFizszN M3jXVXNCVkeHUh?=
BEN MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwNUK4NVUh|ryP MU\TRW5ITVJ?
BFTC-909 NXfsfHVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwNU[yO|Uh|ryP MkfUV2FPT0WU
NCI-H2087 NXnLT|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITvb29KSzVyPUSuOVgyPjRizszN NUG5dZlqW0GQR1XS
RVH-421 M1jpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPQTWM2OD12Lk[2Olkh|ryP MlPrV2FPT0WU
P30-OHK M2DtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILtSItKSzVyPUSuOlgxODhizszN Mn;6V2FPT0WU
NCI-H28 NFjFc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17BeWlEPTB;ND64NVY3OSEQvF2= NYHleIhpW0GQR1XS
ES6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvHTWM2OD12LkizNFE3KM7:TR?= M3HBcHNCVkeHUh?=
769-P MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr4RW5KSzVyPUSuPFU6OjZizszN NHiybphUSU6JRWK=
OE33 NYrQOGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:0eHdKSzVyPUSuPFgyPjFizszN M2PsbXNCVkeHUh?=
SW982 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDITWM2OD12Lkm1NFYyKM7:TR?= MlXQV2FPT0WU
A388 NEW5fndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVwMEK5PFMh|ryP NVfUZ3huW0GQR1XS
TI-73 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW2eJV{UUN3ME21MlA3OTl2IN88US=> Ml\zV2FPT0WU
HCT-116 MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzIN|hKSzVyPUWuNFk5QDlizszN MkO5V2FPT0WU
HuP-T3 NUnSeph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHiNmNKSzVyPUWuNVg4ODlizszN MmjJV2FPT0WU
G-402 NV7teJVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfPeGp6UUN3ME21MlE6PDF4IN88US=> M{G0cXNCVkeHUh?=
NCI-H1792 NGO5THdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLnTWM2OD13LkK0OlIzKM7:TR?= NYjEVIFYW0GQR1XS
NCI-H209 NIfkbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHqSIV7UUN3ME21MlI2QTR{IN88US=> M{nMXnNCVkeHUh?=
NCI-H1650 M1naU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm2bHJKSzVyPUWuN|A3OzRizszN M33X[3NCVkeHUh?=
LCLC-97TM1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf5SYg6UUN3ME21MlMyQDB6IN88US=> Mkn4V2FPT0WU
S-117 NXruTYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;jc3hkUUN3ME21MlM3QTd4IN88US=> MoK1V2FPT0WU
GI-ME-N M2\WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTVwM{m2PFEh|ryP MlLlV2FPT0WU
NCI-H2122 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTVwNEmzPVch|ryP NUixOoh7W0GQR1XS
NCI-H1793 NWX2TJlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTVwNke1PVMh|ryP MUHTRW5ITVJ?
C2BBe1 NHzN[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTVwN{CwPFgh|ryP NGe2UWhUSU6JRWK=
TE-12 M4LMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;mTWM2OD13LkiwOVU3KM7:TR?= NX;KS4VpW0GQR1XS
LCLC-103H NGLpOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrVTWM2OD13LkmxO{DPxE1? MXXTRW5ITVJ?
A673 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PtTmlEPTB;NT65NVk{OiEQvF2= MVfTRW5ITVJ?
BB30-HNC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfPTWM2OD13Lkm4N|Yh|ryP MmXWV2FPT0WU
SF295 NVn1NXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n2WGlEPTB;Nj6wNFQzOiEQvF2= NYfOWow4W0GQR1XS
KU-19-19 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnoOJNmUUN3ME22MlAyPzNzIN88US=> NULwRWRTW0GQR1XS
CFPAC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn34TWM2OD14LkC0OFQ{KM7:TR?= M1nobHNCVkeHUh?=
LoVo MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZwMEWwOlMh|ryP NFLiOo9USU6JRWK=
8505C NVPETldTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmxTWM2OD14LkC3OVc{KM7:TR?= M2rxPHNCVkeHUh?=
GMS-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uzOGlEPTB;Nj6xOVAxOiEQvF2= MWLTRW5ITVJ?
Ca9-22 NV7mOVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvXVG5KSzVyPU[uNVY4OSEQvF2= NVf6bJJTW0GQR1XS
DOK MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTa[ZFKSzVyPU[uNlIxPzJizszN MorrV2FPT0WU
FADU NH;MVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzTTWM2OD14LkK2NFM6KM7:TR?= NHOzPJFUSU6JRWK=
BxPC-3 NYfz[pVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnqTWM2OD14LkK3N|Ih|ryP MkX0V2FPT0WU
CAL-33 M2jNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjyVnY3UUN3ME22MlI6OjBzIN88US=> NH\jU5BUSU6JRWK=
SHP-77 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnraTWM2OD14LkOxOVEzKM7:TR?= NV\iO4l2W0GQR1XS
LXF-289 NHjSNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnZPWtKSzVyPU[uN|M1PTVizszN Mn7wV2FPT0WU
GB-1 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vOTmlEPTB;Nj6zPFIh|ryP M{H2NHNCVkeHUh?=
KS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WxNWlEPTB;Nj6zPFQ1PyEQvF2= NGr1UXlUSU6JRWK=
D-502MG NXK1PZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLNV3FtUUN3ME22MlQzOzd4IN88US=> MYfTRW5ITVJ?
LAN-6 NGDuU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXRTWM2OD14LkWxNFI{KM7:TR?= M2jLb3NCVkeHUh?=
H-EMC-SS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jP[GlEPTB;Nj61OlE1PyEQvF2= MVXTRW5ITVJ?
LC-2-ad NWrETYFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fHR2lEPTB;Nj62NFA4PiEQvF2= M2rZ[HNCVkeHUh?=
NCI-H1693 NYTlc5pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jyUGlEPTB;Nj62NlIyPSEQvF2= MkTkV2FPT0WU
SK-N-FI NGTmeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;MTWM2OD14Lke1NFQ1KM7:TR?= NEnubllUSU6JRWK=
D-423MG MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXaTWM2OD14Lke2NVE4KM7:TR?= MWHTRW5ITVJ?
KNS-42 NUjVTHNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTZwN{ixPVch|ryP MkDoV2FPT0WU
GCT NX\IVZlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XWd2lEPTB;Nj65N|gh|ryP MYnTRW5ITVJ?
DSH1 NFfOS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdwME[zN{DPxE1? NGHuZohUSU6JRWK=
D-247MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zNcGlEPTB;Nz6wO|g5OSEQvF2= NVj5[pZIW0GQR1XS
NCI-SNU-5 NXjmW|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DzfmlEPTB;Nz6xPFM4OSEQvF2= MkjEV2FPT0WU
TE-6 NVvmV3FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHo[mVCUUN3ME23MlIxPjBzIN88US=> NGjKdIJUSU6JRWK=
NOMO-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTdwMkKxNlch|ryP M{OwSnNCVkeHUh?=
NB17 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7zOY5jUUN3ME23MlMxOzB7IN88US=> NXLBTHV[W0GQR1XS
EW-22 NFKxR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTdwM{SzOFgh|ryP M1LpOXNCVkeHUh?=
EW-13 M4HT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTdwM{WxOlIh|ryP NH76ZWtUSU6JRWK=
DOHH-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPpTWM2OD15LkS0NFIh|ryP NF;iT2xUSU6JRWK=
TGBC1TKB NHrpS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPhTWM2OD15LkS5PFk6KM7:TR?= MkntV2FPT0WU
GR-ST NHS4UHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD0TWM2OD15LkWyOVk1KM7:TR?= NGPCO41USU6JRWK=
KYSE-520 NFfKcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PYeGlEPTB;Nz61OVUyPSEQvF2= Mlr0V2FPT0WU
CAPAN-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\PTWM2OD15LkW5OVEh|ryP MoTwV2FPT0WU
HCE-4 NY\neGpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmwOJF2UUN3ME23MlYzOjd7IN88US=> MWfTRW5ITVJ?
MLMA NWrM[GpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvOdmNwUUN3ME23MlYzQTV5IN88US=> MYnTRW5ITVJ?
HT-144 M3:0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S1NWlEPTB;Nz62OVM3QCEQvF2= NIPlT5dUSU6JRWK=
KYSE-180 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[zbYdKSzVyPUeuO|EyPjlizszN MnrhV2FPT0WU
TE-5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTdwOUW5O|Eh|ryP MXHTRW5ITVJ?
IGROV-1 M1zOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nxPWlEPTB;Nz65PFU2OSEQvF2= NELHZlFUSU6JRWK=
NCI-H1581 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRThwMEGyJO69VQ>? MVLTRW5ITVJ?
SW1990 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu5TWM2OD16LkC0OlU6KM7:TR?= NF22b5dUSU6JRWK=
EFM-19 Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3w[|NKSzVyPUiuNFg2PDVizszN MkHLV2FPT0WU
OGR-1 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK2R5hKSzVyPUiuOFMxOjNizszN NX\GWmpSW0GQR1XS
U-118-MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPYTWM2OD16LkSzOFY{KM7:TR?= M1nUd3NCVkeHUh?=
SK-OV-3 NX3iTFVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3scpF3UUN3ME24MlQ3PzZ3IN88US=> M3H0OHNCVkeHUh?=
KNS-62 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwNUG3OlEh|ryP MVzTRW5ITVJ?
GOTO NFj4cmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPFTWM2OD16LkW3OlM2KM7:TR?= Mmn0V2FPT0WU
8305C M1\Qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C0WGlEPTB;OD63NFQ5PCEQvF2= NXjMWWZjW0GQR1XS
RPMI-2650 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrzO3Z1UUN3ME24MlcyQTV3IN88US=> MlfUV2FPT0WU
NEC8 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T6TmlEPTB;OD63OFMxPyEQvF2= M{\jfXNCVkeHUh?=
KYSE-450 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO5THVGUUN3ME24Mlg3PTR6IN88US=> NYHjOGZLW0GQR1XS
RMG-I M1\5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvYTWM2OD17LkG0NFU5KM7:TR?= MkTrV2FPT0WU
CAKI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fORmlEPTB;OT6zNVk4QSEQvF2= NU\ZUmxqW0GQR1XS
KYSE-510 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET6e|VKSzVyPUmuN|U4PzhizszN Ml:4V2FPT0WU
A4-Fuk NWf2[3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LWe2lEPTB;OT6zOlcxOSEQvF2= NXizem42W0GQR1XS
AN3-CA M4D5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTlwNEW0OFQh|ryP MUDTRW5ITVJ?
SK-N-DZ MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq1[XBKSzVyPUmuO|I5PDlizszN M2G5dXNCVkeHUh?=
HSC-2 NESzTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzXTWM2OD17Lke2OlI6KM7:TR?= NEW1bHlUSU6JRWK=
EW-1 M2HGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\1PGlEPTB;OT63PVM3QSEQvF2= NGjBZ4pUSU6JRWK=
D-566MG NGTUOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKw[45KSzVyPUmuPFM3PjRizszN NVK4Z|NNW0GQR1XS
COLO-792 NIDPZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTlwOUi3OFYh|ryP Mm\xV2FPT0WU
TE-10 NIPy[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFyLkCzPVYh|ryP NVfrVlBsW0GQR1XS
NCI-H650 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTsVY5zUUN3ME2xNE41Ojh4IN88US=> MXrTRW5ITVJ?
U-266 M3G2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFyLkS1OUDPxE1? NGPkZpNUSU6JRWK=
Detroit562 NXHsT5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{iwfWlEPTB;MUGuNFUyPSEQvF2= M4nFO3NCVkeHUh?=
NH-12 M12zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17GOmlEPTB;MUGuNVQ1PiEQvF2= NFvQ[ndUSU6JRWK=
CO-314 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizU5lKSzVyPUGxMlI5PDJizszN M{TQXHNCVkeHUh?=
IST-MEL1 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3HRVVRUUN3ME2xNU42OzJ|IN88US=> NV\oc2dWW0GQR1XS
KNS-81-FD MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnnTWM2OD1zMT61OVI4KM7:TR?= NX3wOGk1W0GQR1XS
SW1463 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPJ[ZZbUUN3ME2xNU42QTh7IN88US=> MXHTRW5ITVJ?
NCI-H23 NIrIbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PmfGlEPTB;MUGuOlU2OiEQvF2= MYnTRW5ITVJ?
SK-MEL-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFzLkexPVch|ryP MWTTRW5ITVJ?
NB13 NEDWd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF{LkG0PVUh|ryP MXnTRW5ITVJ?
Daoy MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zNVmlEPTB;MUKuNlg2PiEQvF2= MWXTRW5ITVJ?
NCI-H1623 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r4dmlEPTB;MUKuN|gxOSEQvF2= MnrhV2FPT0WU
NMC-G1 NVf3U5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\wOGlEPTB;MUKuO|E4KM7:TR?= M1TYO3NCVkeHUh?=
DK-MG NH;yRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF{Lkm0PFIh|ryP MU\TRW5ITVJ?
TCCSUP MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwTWM2OD1zMz6xNlg1KM7:TR?= MnfoV2FPT0WU
SCC-15 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliwTWM2OD1zMz6yOlUyKM7:TR?= MUPTRW5ITVJ?
NOS-1 NVO4dlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T1PGlEPTB;MUOuNlg6OyEQvF2= MYTTRW5ITVJ?
RH-1 M1\BWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrN[VF4UUN3ME2xN{4{ODN5IN88US=> M2HUTXNCVkeHUh?=
SK-MEL-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HUbGlEPTB;MUOuN|czQCEQvF2= Ml\FV2FPT0WU
NB5 M4OzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\IbXFKSzVyPUGzMlQxPjdizszN MnHLV2FPT0WU
SNU-387 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\PV5lKSzVyPUGzMlUxPzJizszN NX\IZ|YzW0GQR1XS
CAL-120 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF|Lk[3NVgh|ryP MXvTRW5ITVJ?
Mo-T NHHYSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\RR2lEPTB;MUOuO|A4KM7:TR?= Mn3YV2FPT0WU
LNCaP-Clone-FGC M3K5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjhNVJKSzVyPUGzMlc6QTJizszN NVez[XNZW0GQR1XS
CAN M3myZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jBSmlEPTB;MUSuNFI5QCEQvF2= M3f4SnNCVkeHUh?=
SK-MEL-30 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W1VGlEPTB;MUSuNFY{KM7:TR?= MXzTRW5ITVJ?
COLO-678 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfhTFVUUUN3ME2xOE4xQDJ{IN88US=> MkjaV2FPT0WU
SCC-9 M2XLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfCTWM2OD1zND6xNFIyKM7:TR?= MnfkV2FPT0WU
KINGS-1 NGnRRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXMVVNKSzVyPUG0MlE1ODJizszN MXrTRW5ITVJ?
SL-513 NH3ibHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHhTWM2OD1zND6xPFch|ryP MYXTRW5ITVJ?
HLE NV3Rc29wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S3bGlEPTB;MUSuN|g2OiEQvF2= NFztVVZUSU6JRWK=
SW1573 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\KcGlEPTB;MUSuOFQ{PSEQvF2= NUXHVlI5W0GQR1XS
KYSE-140 NGniSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZd5RRUUN3ME2xOE43OzJ5IN88US=> NX\nOVZ3W0GQR1XS
SK-PN-DW NX[1SmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPYNGhKSzVyPUG0MlgxODFizszN MmDhV2FPT0WU
A253 M4LLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF3LkC2NlUh|ryP MmPmV2FPT0WU
CAL-12T M4mwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PDNWlEPTB;MUWuOFY3OiEQvF2= Mlz6V2FPT0WU
COLO-679 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzjfnVKSzVyPUG1Mlc3QDNizszN M2XHRXNCVkeHUh?=
UACC-257 NWrmbnpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfuN5VKSzVyPUG2MlEzODFizszN NIDxRZdUSU6JRWK=
U-87-MG NX;0OXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTPTWM2OD1zNj6zOVI{KM7:TR?= MWnTRW5ITVJ?
HCC1806 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrlfoxKSzVyPUG2MlcxPzFizszN NETMW2pUSU6JRWK=
NCI-H2170 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIOzeHRKSzVyPUG3MlI1PDhizszN Ml3OV2FPT0WU
AGS M4TDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF5LkO4NFgh|ryP NVvpU4lxW0GQR1XS
MEL-HO NHPZclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm5UItKSzVyPUG3Mlc2ODNizszN MlXNV2FPT0WU
SW48 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDTG9KSzVyPUG3Mlc4OTZizszN M3nzR3NCVkeHUh?=
HuP-T4 MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PLcGlEPTB;MUiuNFIxPiEQvF2= NYPrNYtzW0GQR1XS
NCI-H720 NXTqTo03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TxZWlEPTB;MUiuNVQxOiEQvF2= Mlf5V2FPT0WU
RCC10RGB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DFT2lEPTB;MUiuNVY6PyEQvF2= NInwPGZUSU6JRWK=
HD-MY-Z M3PqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF6LkKyOVQh|ryP MUnTRW5ITVJ?
A427 M4TGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPmT|A4UUN3ME2xPE42ODl2IN88US=> NF3aR|FUSU6JRWK=
HCC2998 M{jtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF6Lk[wOVEh|ryP NWTEephNW0GQR1XS
EPLC-272H NH32c3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH6SlhTUUN3ME2xPU4xPDN2IN88US=> MYTTRW5ITVJ?
C32 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD3TWM2OD1zOT6wOFUh|ryP MXrTRW5ITVJ?
UMC-11 NVrGRWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT4TWM2OD1zOT6yNVI{KM7:TR?= NFPhdVFUSU6JRWK=
CaR-1 NH;ZSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jBRWlEPTB;MUmuOlgxPCEQvF2= NX\YXZhpW0GQR1XS
KYSE-410 NUC0ZnJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\sT2lEPTB;MUmuPVE{QSEQvF2= NEKyVWZUSU6JRWK=
HuCCT1 NICw[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fnU2lEPTB;MkCuOlI6PCEQvF2= M3jsS3NCVkeHUh?=
LB996-RCC M1W1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjqWpM4UUN3ME2yNE44OTZ6IN88US=> NUX2Z3NnW0GQR1XS
KYSE-70 NWLaWmZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XXeWlEPTB;MkCuPFA2QSEQvF2= MmDyV2FPT0WU
CAL-72 NETmPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG0TWM2OD1{MD65NVUh|ryP NHXod|BUSU6JRWK=
Capan-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\jTWM2OD1{MT6wOFE{KM7:TR?= NV2yXmZHW0GQR1XS
PANC-08-13 NXGzcY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvoTWM2OD1{MT6yOVE2KM7:TR?= Ml7WV2FPT0WU
SBC-1 NVPLcIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LYS2lEPTB;MkGuN|A5OSEQvF2= MoDhV2FPT0WU
MFM-223 M3fLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LySGlEPTB;MkGuN|M1OiEQvF2= MljmV2FPT0WU
BB49-HNC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\nRXFKSzVyPUKxMlU4OTZizszN MnXZV2FPT0WU
SH-4 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LKUGlEPTB;MkGuOlYyQCEQvF2= M1nROHNCVkeHUh?=
HuO9 NWrPc2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T2dmlEPTB;MkGuPVgzPSEQvF2= M1TKdXNCVkeHUh?=
AM-38 NVvEcYlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofDTWM2OD1{Mj6wOFg2KM7:TR?= NUfzWGRRW0GQR1XS
A431 NUny[XRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLPTWM2OD1{Mz6yNVE6KM7:TR?= MmHsV2FPT0WU
YAPC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHvZmJqUUN3ME2yN{4zPjVzIN88US=> MUDTRW5ITVJ?
LU-139 NIDBbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe2PZUyUUN3ME2yN{41QDB7IN88US=> MY\TRW5ITVJ?
HEC-1 NUnucVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ|LkS5N|ch|ryP NUD5TG9{W0GQR1XS
SCC-25 M1L6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nFVGlEPTB;MkSuN|AxPiEQvF2= MYXTRW5ITVJ?
HT-29 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ2LkO4NlMh|ryP M2nmSnNCVkeHUh?=
PC-14 NWHXRmxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjqUVJKSzVyPUK0MlY2PzFizszN NHvCOIlUSU6JRWK=
Calu-6 M4jVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17WNmlEPTB;MkWuOVA4OSEQvF2= MkjDV2FPT0WU
SJRH30 NXi4UmlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofMTWM2OD1{NT62OFk3KM7:TR?= M3TiRXNCVkeHUh?=
ChaGo-K-1 M3\Temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16xd2lEPTB;Mk[uNVYzQSEQvF2= M3;1OXNCVkeHUh?=
IA-LM M3zZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ4LkO2OFUh|ryP NIjDNVNUSU6JRWK=
GP5d NVTmR|ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j0bWlEPTB;Mk[uOFQ6OSEQvF2= MkXpV2FPT0WU
NCI-H2291 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjETWM2OD1{Nj62OVQyKM7:TR?= MnnyV2FPT0WU
BALL-1 NU\KRYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ4LkmzPVch|ryP M1XuW3NCVkeHUh?=
HCC1954 M1;nfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ4Lkm4NFgh|ryP NFfQb4JUSU6JRWK=
NCI-H2452 M1H3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ5LkSxOlMh|ryP MVjTRW5ITVJ?
LU-99A MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfLR|A4UUN3ME2yO{42PTh{IN88US=> MmTvV2FPT0WU
NTERA-S-cl-D1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXIfZNKSzVyPUK3MlczQTlizszN MULTRW5ITVJ?
PANC-10-05 NUXyZZF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjYOHo1UUN3ME2yO{44Pzd3IN88US=> MXHTRW5ITVJ?
NCI-H2405 M361cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7UNVNuUUN3ME2yO{46Ozh5IN88US=> NHvFN3pUSU6JRWK=
MDA-MB-415 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ6LkSxN|ch|ryP MYfTRW5ITVJ?
NCI-H2342 M3vwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH0b5hsUUN3ME2yPE42OjhzIN88US=> M4XBb3NCVkeHUh?=
TGBC24TKB NYj1VotkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD6[YNKSzVyPUK4MlcyOTdizszN Mkm3V2FPT0WU
LU-134-A M3S4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfydIZDUUN3ME2yPE46OjZzIN88US=> M2HQTXNCVkeHUh?=
SCC-4 M2GyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTNzLkC0PVQh|ryP MlXtV2FPT0WU
Saos-2 M4rVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m2eWlEPTB;M{GuPVMxPiEQvF2= NGD6RZhUSU6JRWK=
RERF-LC-MS NIrud2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm2TWM2OD1|Mj64NlMyKM7:TR?= NFjvXFdUSU6JRWK=
M14 NX20fpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXCTWM2OD1|Mj65O|Y1KM7:TR?= MmPVV2FPT0WU
HPAF-II MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r1ZmlEPTB;M{OuOVAyOSEQvF2= M4PVdHNCVkeHUh?=
NCI-H1755 M37XeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TFWWlEPTB;M{SuN|MxPSEQvF2= MYjTRW5ITVJ?
D-392MG NWLk[ZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDuTWM2OD1|NT64Olc1KM7:TR?= M3jLOHNCVkeHUh?=
A704 M1fUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN4LkC0Nlch|ryP MW\TRW5ITVJ?
CP50-MEL-B NUW5NHFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN4LkG5NVEh|ryP MVfTRW5ITVJ?
EW-18 M{jZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDNTWM2OD1|Nj60OVIh|ryP MYfTRW5ITVJ?
WM-115 M2D6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLkTWM2OD1|Nj64NFk6KM7:TR?= MoDrV2FPT0WU
LU-65 NEDiN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr2SYVtUUN3ME2zO{4yPDF5IN88US=> MULTRW5ITVJ?
NCI-H1563 NH[1R2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHziXHBKSzVyPUO3MlI1QDRizszN NYnDcHNWW0GQR1XS
DBTRG-05MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTN6LkC2PVEh|ryP NFzVXnRUSU6JRWK=
NCI-H630 M2PlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6xOYJKSzVyPUO4MlQ4OTRizszN NIjGWZpUSU6JRWK=
NCI-H1155 NGfU[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTN7LkK0NkDPxE1? NHLVbYtUSU6JRWK=
OVACR-3 M1izbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M332VWlEPTB;M{muPVE6PSEQvF2= MXzTRW5ITVJ?
OAW-42 NHrj[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTRyLkSyOVgh|ryP NVjGUJA{W0GQR1XS
JVM-2 M1GwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DseGlEPTB;NEGuNlQyPSEQvF2= NXXQblhDW0GQR1XS
C3A NGnzcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T4U2lEPTB;NEGuN|Q1PyEQvF2= MoDxV2FPT0WU
HT55 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLvTWM2OD12Mj6yPFQyKM7:TR?= NUDVN5l5W0GQR1XS
OVCAR-4 NXr3OXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTR{LkK5O|Qh|ryP NUS3T5BNW0GQR1XS
MEG-01 NVPtW5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnKWYJtUUN3ME20Nk41PjF4IN88US=> NWHsO2FWW0GQR1XS
NCI-H82 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\4Z3BKSzVyPUSzMlk5QTJizszN NU\jSFBCW0GQR1XS
JEG-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17CeGlEPTB;NESuPVQ4KM7:TR?= NWfEN5h2W0GQR1XS
BPH-1 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTR4LkO5PVgh|ryP Mn;zV2FPT0WU
MPP-89 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTR5LkK4PVgh|ryP M3XvXXNCVkeHUh?=
ALL-PO M1fFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G0NWlEPTB;NEeuOFE5QCEQvF2= NEjoeVNUSU6JRWK=
HT NFLGcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjGUJdGUUN3ME20O{41QTJizszN MXrTRW5ITVJ?
NCI-H2347 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR6LkC3NVUh|ryP NXfUcplCW0GQR1XS
A2780 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX6cWNUUUN3ME20PU41OjJ6IN88US=> M2GxXHNCVkeHUh?=
KARPAS-299 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[3TWM2OD12OT61NVE6KM7:TR?= NYW5OmRtW0GQR1XS
NCI-H1651 NXnpRllVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LYVGlEPTB;NEmuPFgzOSEQvF2= MkDjV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[1]
+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験：

[1]
+ 展開
  • 細胞株： Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度： 0.01-1 μM
  • 反応時間： 24 hours
  • 実験の流れ：

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験：

[1]
+ 展開
  • 動物モデル： Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤： Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量： 0-150 mg/kg
  • 投与方法： Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。 		6 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl
CAS No. 827022-32-2
保管 粉
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer January 7 2019 Phase 2
NCT03691493 Not yet recruiting Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 Emory University|Pfizer December 1 2018 Phase 2
NCT03530696 Not yet recruiting HER2-positive Breast Cancer|Breast Cancer|Breast Cancer Stage|Recurrent Breast Cancer|Metastatic Breast Cancer|HER2 Positive Breast Carcinoma University of Arizona|Pfizer November 30 2018 Phase 2
NCT03531645 Not yet recruiting Malignant Neoplasms of Female Genital Organs M.D. Anderson Cancer Center|AstraZeneca|Pfizer November 2018 Phase 2
NCT03644186 Not yet recruiting Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer International Breast Cancer Study Group|Pfizer|Hoffmann-La Roche October 2018 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須
selleck catalog

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

  • Most Potent CDK Inhibitor

    LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

相関CDK製品

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID